Published in final edited form as:

Alzheimers Dement. 2018 August ; 14(8): 981–988. doi:10.1016/j.jalz.2018.03.005.

Lifetime Risks of Alzheimer's Disease Dementia Using Biomarkers for Preclinical Disease

Ron Brookmeyer, Ph.D. and

Department of Biostatistics, University of California, Los Angeles, CA 90095

Nada Abdalla, M.S.

Department of Biostatistics, University of California, Los Angeles, CA 90095

Abstract

Introduction—Lifetime risks are the probabilities of progressing to AD dementia during ones' lifespan. Here we report the first estimates of the lifetime and ten-year risks of AD dementia that account for age, gender and biomarker tests for preclinical disease.

Methods—We used a multistate model for the disease process together with U.S. death rates.

Results—Lifetime risks of AD dementia vary considerably by age, gender and the pre-clinical or clinical disease state of the individual. For example, the lifetime risks for a female with only amyloidosis are 8.4% for a 90 year old and 29.3% for a 65 year old. Persons younger than age 85 with mild cognitive impairment, amyloidosis and neurodegeneration have lifetime risks of AD dementia greater than 50%.

Discussion—Most persons with preclinical AD will not develop AD dementia during their lifetimes. Lifetime risks help interpret the clinical significance of biomarker screening tests for AD.

1. INTRODUCTION

Considerable advances have been made in identifying biomarkers that detect preclinical Alzheimer's disease (AD) [1–3]. Biomarkers are central to current research on AD pathophysiology, although their utility in routine clinical care is less clear for several reasons. First, the biomarkers that are currently in use are based on imaging or cerebrospinal fluids and are either expensive, invasive or both. Second, even if preclinical disease is detected there are no interventions strongly supported by the scientific evidence to slow the onset of dementia, although, cognitive training, blood pressure management and physical

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Authors Contributions:

RB conceived the study, developed the methods, interpreted the data and drafted the manuscript. NA carried out statistical analyses, developed the computer software code and critically revised the manuscript.

Declaration of Interests:

RB reports grants from National Institutes of Health and fees from Takeda Inc. for serving as a member of a data safety monitoring board. NA has nothing to disclose.

activity may provide some benefit [4]. Third, persons with preclinical disease may never actually experience any clinical symptoms during their lifetimes because of the long preclinical period of AD and the high mortality rates in elderly populations.

The lifetime risk is the probability that an individual experiences a clinical condition prior to death [5]. Lifetime risks for AD dementia have been based on longitudinal follow-up of cohorts such as the Framingham study [6]. To date, no lifetime risk estimates for AD dementia have been reported that account for biomarkers of preclinical conditions. Lifetime risk estimates address a critical question for clinicians, patients and their families as to the likelihood that a preclinical condition detected by biomarker screening will ever actually manifest itself with clinical symptoms during a person's natural lifespan.

Here, we report estimates of the lifetime and ten-year risks of AD dementia based on age, gender and biomarker tests for preclinical disease. The estimates are based on a multistate model for the progression of AD through preclinical and clinical disease states.

2. METHODS

In this section we provide an overview of the methods including the multistate model and transition rates used in the model. The Supplementary Material provides technical details including definitions and cutoffs of biomarker defined states and the estimating equations.

2.1 Multistate Model

We used a multistate model for the progression of AD through preclinical and clinical disease states to estimate lifetime risks of AD dementia. The model is based on the National Institute of Aging-Alzheimer's Association (NIA-AA) framework for the preclinical stages of AD [1]. The NIA-AA framework of pre-clinical disease postulates that the AD pathophysiology typically begins with state of asymptomatic amyloidosis, that is Amyloid β ($A\beta$) deposition, which can be detected by specific biomarkers for $A\beta$ accumulation such as positron emission tomography (PET) amyloid imaging or low $A\beta$ 42 in the cerebrospinal fluid (CSF). The disease process advances to neurodegeneration which can be detected by biomarkers including elevated CSF tau, neuronal dysfunction based on fluorodeoxyglucose (FDG) PET, or hippocampal atrophy/cortical thinning on volumetric magnetic resonance imaging (MRI). Subsequently, clinical signs and symptoms emerge including subtle cognitive decline, onset of mild cognitive impairment due to AD and ultimately AD dementia [7, 8].

The multistate model we utilized is illustrated in Figure 1. The model postulates that one pathway that leads to AD dementia (red pathway in Figure 1) that is consistent with the amyloid hypothesis of AD [9] is sequential progression through the following states: normal (state 1); asymptomatic amyloidosis (state 2); amyloidosis and neurodegeneration (state 4); mild cognitive impairment due to AD with both amyloidosis and neurodegeneration present (state 5); and, AD dementia (state 7). Evidence supporting alternative pathways leading to AD dementia has also been described including the occurrence of Alzheimer's dementia in the absence of amyloidosis or with neurodegeneration arising prior to amyloidosis [10]. We allow for these alternative pathways (blue pathways in Figure 1), although we recognize

there is controversy as to whether such pathways should or should not be considered part of the AD pathological processes [11, 12]. Persons are at risk of death in any preclinical or clinical disease state. The multistate model in Figure 1 differs from the NIA-AA framework in that we do not include a stage of amyloidosis and neurodegeneration with subtle cognitive decline because we do not believe there is adequate data to provide reliable estimates of transition rates to and from that stage, and instead that stage is included in state 4 in Figure 1. The model also differs from the multistate model utilized by Jack and colleagues [13] to estimate transition rates in that we include an AD mild cognitive impairment state with both amyloidosis and neurodegeneration present (state 5) and a mild cognitive impairment state with only neurodegeneration present (state 6). The model in Figure 1 is similar to a model we previously used for obtaining population forecasts for preclinical and clinical disease states [14] with the difference being that for the purpose of estimating lifetime risks we model only the disease process up to the onset of AD dementia and not its subsequent clinical course.

The multistate model is a discrete time Markov model in which the transition rates from one state to the next are allowed to depend on a person's current age but not on the duration of time that a person has already spend in the state. Transitions are assumed to occur at the end of each chronological year of age.

2.2 Transition rates and death rates

The transition rates we used in the multistate model are based on two large published epidemiological cohort studies that measured biomarkers for amyloidosis and neurodegeneration. One study, The Mayo Clinic Study of Aging analyzed 1541 participants and reported preclinical transition rates between biomarker states [13]. The second study based on 13 cohorts in Europe and the United States reported on the rates of progression from MCI to AD dementia and included at least 3 years of follow-up on 353 persons with MCI and both amyloidosis and neurodegeneration present and another 222 persons with MCI and neurodegeneration present [15]. We have previously described the use of these epidemiological cohort studies for estimating each of the transition rates in the multistate model [14].

We used U.S 2014 death rates by age and gender for persons in the pre-clinical states 1 through 4 and assumed those death rates remained constant into the future [16]. Recent studies have indicated persons with mild cognitive impairment (MCI) are at an increased risk of death compared to persons without MCI [17–21]. A study from the population-based Mayo Clinic Study of Aging reported that the hazard ratio of death for persons with amnesic MCI prior to onset of dementia relative to cognitively normal persons was 1.65 [17]. Similar hazard ratios have been reported in other studies [18–21]. We multiplied the background death rates by the factor 1.65 to obtain the death rates for persons with mild cognitive impairment in states 5 and 6.

2.3 Lifetime Risk Estimation

The lifetime risk is the probability of developing AD dementia during one's lifetime. We calculated lifetime risks accounting for preclinical or clinical disease state (states 1-6), age

and gender. Gender is factored into the calculations because death rates depend on gender. Age is factored in because death rates and transition rates between states depend on age. In addition we calculated 10-year (absolute) risks which are the probabilities of developing AD dementia over the next 10 years. The 10- year risk (also called the absolute risk) are the probabilities of developing a clinical condition over a restricted time period (e.g., 10 years) while the lifetime risk is that probability over the entire remaining lifespan [22, 23]. The Supplementary material provides the equations that were utilized to calculate the lifetime and 10-year risks. In brief, first, we calculated the probability that a person who is in disease state i at age a develops AD dementia (state 7) at age $a+n$. We calculated that probability by multiplying one step transition matrices n times (see Supplementary Material). Second, we calculated the 10-year risk of AD dementia by summing those probabilities for each of the next 10 years (that is for $n=1, 2, \dots, 10$). The lifetime risk was obtained by summing those probabilities of the occurrence of AD dementia at each age from age $a+1$ until age 109 (the maximal lifespan was assumed to be 109).

2.4 Sensitivity Analyses and Comparison with other Approaches

We performed a sensitivity analysis of the lifetime and 10-year risk estimates to the transition rates. We calculated ranges that resulted from using a high and low series of transition rates. The high and low series of transition rates were based on the limits of the 95% confidence intervals for each transition rate.

We sought to determine if our estimates of lifetime risks could be corroborated by other independent data sources and methods. Unfortunately, there have been no previous studies of lifetime risks of AD dementia that account for preclinical disease state using biomarkers. AD dementia lifetime risks reported from the Framingham Heart Study which were based on observation of AD dementia diagnoses and mortality during longitudinal follow-up, accounted for age and gender but did not account for biomarkers or preclinical disease states [5, 6]. Thus, in order to make comparisons we needed to calculate weighted averages of our multistate model lifetime risk estimates averaging over the six preclinical and clinical disease states where the weights were based on the prevalence rates of each of the states by age and gender (see Supplementary Material). We also compared these estimates with lifetime risks for all-cause dementia from three studies: a study [24] using data from the Rotterdam Study which is a community based prospective cohort study in the Netherlands [25]; a study [26] using data from the Aging Demographics and Memory Study (ADAMS) which is a nationally representative U.S. longitudinal study [27]; and a study [28] using data from the Canadian Study of Health and Aging [29]. Finally, we discuss results from studies that estimated the proportions of deaths in the United States either attributable to AD dementia or with AD dementia present at death [30, 31] in relation to the lifetime risk estimates reported here.

3. RESULTS

Table 1 shows the lifetime risks of AD dementia for females by preclinical or clinical disease state and age based on the multistate model. We find that the lifetime risks at each age increase in the following order by disease state: normal (state 1), neurodegeneration

(state 3), amyloidosis (state 2), amyloidosis and neurodegeneration (state 4); MCI with neurodegeneration (state 6); and MCI with amyloidosis and neurodegeneration (state 5). We also observe in Table 1 that the lifetime risks generally decrease with age for persons in any given disease state. The explanation for the decreasing trend of lifetime risks with age within each disease state in Table 1 is that the expected remaining lifetime in which to progress to AD dementia decreases with advancing age.

The lifetime risks in Table 1 vary considerably by age and disease state. For example, the lifetime risks for a 75 years old female are: 13.8% in the normal state; 23.5% with amyloidosis; 35.9% with amyloidosis and neurodegeneration; and 84.7 % with MCI in the presence of both amyloidosis and neurodegeneration. We find that presence of preclinical disease does not necessarily signal a high likelihood of AD dementia. For example, a 90 year old with amyloidosis (state 2) has a lifetime risk of AD dementia of only 8.4% compared to a 65 year old female with amyloidosis who has a lifetime risk of 29.3%. The lower lifetime risk for the 90 year old versus the 65 year old is explained by the shorter life expectancy of the 90 year old compared to the 65 year old. Mild cognitive impairment in the presence of both amyloidosis and neurodegeneration confers a lifetime risk of at least 50% for all ages less than or equal to 85.

Table 2 shows the 10-year absolute risks of AD dementia for females according to disease state and age. The 10- year risks are useful for identifying which persons are most likely to progress to AD dementia in the near term and for whom prevention interventions to delay disease progression are especially urgent. Ten-year (or shorter term) risks provide a time perspective on lifetime risks and aid in assessing health care and resource needs in the short term. The 10-year (or shorter term) risks also aid in designing clinical trials by identifying the persons at highest risk of progression to the primary clinical endpoints (e.g., AD dementia) in order to increase statistical power, and to identify those persons for whom there is significant potential benefit from trial enrollment [23]. The 10-year risks are necessarily less than lifetime risks and the differences between them can vary considerably. For example, a 65 year old female with amyloidosis (state 2) has a 10-year risk of AD dementia of 2.5% but a lifetime risk of 29.3%. In contrast, the 10 year risk for a 90 year old with amyloidosis (8.2%) is essentially indistinguishable from her lifetime risk (8.4%). Those findings are explained by the shorter life expectancy (less than 10 years) for 90 year olds compared to 65 year olds.

Table 3 shows the lifetime risks of AD dementia for males by preclinical and clinical disease state and age. The lifetime risks of males are less than the lifetime risks for females because mortality rates are higher for males than females. For example, the lifetime risks for a 75 year old male and female with amyloidosis (state 2) are 17.2% and 23.5% respectively. Generally, the trends and patterns of lifetime risks with age and disease state for males are similar to that observed with females. Table 4 shows the 10-year absolute risks of AD dementia for males. The 10- year risk of AD dementia for a male with amyloidosis (state 2) is less than 10% for all ages.

Table 5 compares lifetime risk estimates of AD dementia by age and gender (but not biomarker preclinical state) obtained from the multistate model with several other studies.

The Framingham Study reported lifetime risks of AD dementia by age and gender. The Framingham estimates are lower than the estimates from the multistate model, especially for males, although the ranges overlapped. For example, the lifetime risks for males at age 75 were 21.1% (range 11.2-34.8%) and 10.2% (95% CI, 7.9-12.5%) based on the multistate model and Framingham study, respectively. A possible explanation [26] for the lower risks in Framingham is that death rates were generally higher during the follow-up period of the Framingham Study (which was centered approximately around the year 1985) than U.S. death rates in 2014 which was what was used in the multistate model. If death rates are higher, then lifetime risks of AD dementia will be lower. Table 5 also shows lifetime risks for all-cause dementia based on data from the Rotterdam study [24] and the ADAMS study [26]. The lifetime risks of all-cause dementia from these studies are higher than that for AD dementia from either the multistate model or Framingham Study. Another study of lifetime risks of all-cause dementia risks [28] was based on the Canadian Study of Health and Aging and reported even higher estimates than that based on ADAMS and Rotterdam. The Canadian study reported lifetime risks of all-cause dementia (not stratified by gender) at ages 65, 75 and 85 of 42.4%, 47.3% and 58.5%, respectively [28].

Two other studies on AD and mortality are relevant to the question at hand, although these studies did not directly estimate lifetime risks [30, 31]. One study based on data from the Chicago Health and Aging Project (CHAP) found that approximately 600,000 deaths in the U.S. occurred among persons over the age of 65 with AD present in 2010 which represented approximately 32% of all U.S. deaths over the age of 65 [30,32]. A second study using data from multiple sources including CHAP, the Rush Memory and Aging Project and the Religious Order Study concluded that approximately 503,400 deaths in the U.S. among persons age 75 and older were attributable to AD dementia in 2010, which represents approximately 36% of deaths over the age of 75 [31,32]. The results from these two studies [30, 32] suggested that AD dementia is present in well over 30% of U.S. deaths among elderly persons, a percentage that is higher than any of the multistate model lifetime risk or Framingham estimates in Table 5. To summarize, compared to the lifetime risk of AD dementia from the multistate model reported here, two mortality studies [30,31] suggested higher risks, while the Framingham study [5,6] suggested lower risks.

4. DISCUSSION

The prevalence of preclinical AD in the United States has been estimated to be approximately 46.7 million persons [14]. Tables 1 and 3 show that most persons with preclinical disease will not develop AD dementia during their lifetimes. We find that the lifetime risks for AD dementia vary considerably by age, gender and preclinical disease state. If interventions could slow disease progression rates even modestly, lifetime risks of AD dementia could be appreciably reduced [33].

Lifetime risks are useful from a number of perspectives. Lifetime risks calculations can provide guidance as to whether biomarker screening would provide clinically useful prognostic information. For example, the lifetime risks of AD dementia for 90-year males and females who do not have cognitive impairment are less than 12.4% and 16.9%, respectively. Thus, 90-year olds who do not have cognitive impairment are unlikely to

develop AD dementia during their lifetime regardless of their current preclinical state, and thus biomarker screening would not yield much additional prognostic information. In some situations, lifetime risks may allay some anxiety about the meaning of a particular positive screening test with regard to the likelihood of developing AD dementia. For example, the lifetime risk of AD dementia of a 60-year old male with amyloidosis is only 23%, and thus, he is considerably more likely to not develop than to develop AD dementia. Lifetime risks also explain help some discordance between clinical and pathological studies. Some studies have reported persons with AD brain pathology who do not have AD dementia at the time of death. Lifetime risks can help explain that discordance. For example, while 23% of 60-year old males with amyloidosis will ultimately develop AD dementia, the flip-side is that 67% of 60-year olds with amyloidosis will die prior to onset of AD dementia.

Key sources of uncertainty in our results are the transition rates between disease states. The transition rates were based on some of the largest longitudinal studies available to date that have measured biomarkers. We provided ranges for the lifetime risks based on confidence intervals for the transition rates. However we recognize that there are important potential sources of bias that may not be accounted for by these ranges. For example, while the Mayo Clinic Study of Aging is a population based cohort study, it is not ethnically diverse. Furthermore, vascular risk factors and pathology in the presence of AD pathology may increase the transition to AD dementia, and thus the transition rates we used may not be applicable to other populations with different levels of vascular pathology. Future studies of transition rates in more ethnically diverse populations that also account for education and other sociodemographic characteristics and with varying prevalence rates of vascular pathology will be important. We also acknowledge that the preclinical transition rates depend on the specific biomarkers and cut points used in defining the preclinical states. It is reassuring that one study suggested that results are not sensitive to the definitions of the states of amyloidosis and neurodegeneration [34]. Furthermore, it is reassuring that AD incidence rates produced by the multistate model were consistent with a worldwide systematic review of clinical AD dementia incidence based on 27 cohorts from around the world (see figure 4 in [14]).

The disease transition rates in our model were allowed to depend on chronological age but they did not depend on calendar time. Recent reports have suggested that dementia prevalence and incidence rates have declined over the past three decades [35,36]. The disease transition rates we utilized were based on recent follow-up of cohorts and thus should reflect current AD dementia rates. However, if AD dementia incidence rates decline in the future, then the lifetime risks reported here would overestimate actual risks.

Important inputs into our calculations are the death rates. The lifetime risk estimates vary inversely with death rates; as death rates increase the lifetime risks of AD dementia decrease [37]. Our lifetime and 10-year risk estimates are based on 2014 U.S mortality rates and as such may not be applicable to other populations. Furthermore, if mortality rates decline in the future, and all other factors remaining the same, then the lifetime risks reported here would underestimate actual risks. We adjusted for excess mortality in the mild cognitive impairment state, but if the adjustment factor (relative risk of 1.65) that we used was too high (low) then our lifetime AD dementia risks would be too low (high).

An important question is whether supplementary information on Apolipoprotein (APOE) $\epsilon 4$ carrier status, in addition to that on preclinical biomarkers, would refine lifetime risk estimates. Some studies have suggested that APOE $\epsilon 4$ carriers are at increased risk of developing amyloidosis [38–41]. Suppose the effect of APOE $\epsilon 4$ carrier positivity is to increase the incidence of amyloidosis but to not alter the subsequent disease course after amyloidosis has occurred; that is, suppose its effect is to increase the rates of transition from normal (state 1) to amyloidosis (state 2) and from neurodegeneration (state 3) to amyloidosis and neurodegeneration (state 4)), but to not alter any other transition rates in the multistate model. Under that supposition, information on APOE $\epsilon 4$ carrier status would alter the lifetime risks for persons without amyloidosis (persons in states 1, 3 and 6), but would not alter the risks among persons with existing amyloidosis (persons in states 2, 4 and 5). Further studies are necessary to precisely quantify the impact of APOE $\epsilon 4$ status on each of the preclinical transition rates as well as to identify other risk factors that in combination with biomarkers of preclinical disease would yield more precise estimates of lifetime risk of AD dementia.

Pathologies related to non-AD dementias may coexist with AD pathologies. It is uncertain whether multiple mixed pathologies act independently or synergistically on risk of all cause dementia. Extensions of the multistate model to include additional preclinical states that are either specific to AD (e.g., biomarkers for tau pathology [42]) or biomarkers related to other types of dementia would refine estimates of lifetime risks of AD dementia as well as all-cause dementia.

Guidelines for the appropriate clinical use of screening tests for preclinical AD and mild cognitive impairment will be increasingly important [43,44] as the sensitivity and specificity of biomarkers for preclinical AD improve, and as intervention options to slow disease progression become available. There are numerous critical factors [45, 46] to consider in assessing the value of screening for AD biomarkers. Lifetime risks will aid in formulating screening guidelines by identifying groups of persons for whom screening for preclinical AD may be most useful and by helping interpret the clinical significance of biomarker screening tests for preclinical AD.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This study was supported by a grant from the National Institutes of Health (R21AG055361). The study sponsor had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit the article for publication.

References

1. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Park DC. Toward defining the preclinical stages of AD: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for AD. *Alzheimer's & Dementia*. 2011; 7:280–292.

2. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *The Lancet Neurology*. 2010; 9:119–128. [PubMed: 20083042]
3. Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, Gunter JL, Senjem ML, Jones DT, Kantarci K, Machulda MM. Defining imaging biomarker cut points for brain aging and AD. *Alzheimer's & Dementia*. 2017; 13:205–16.
4. National Academies of Science, Engineering and Medicine. Preventing Cognitive Decline and Dementia: A Way Forward. Washington, DC: The National Academies Press; 2017.
5. Seshadri S, Wolf PA. Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. *The Lancet Neurology*. 2007; 6:1106–14. [PubMed: 18031707]
6. Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Au R, Kannel WB, Wolf PA. The lifetime risk of stroke. *Stroke*. 2006; 37:345–50. [PubMed: 16397184]
7. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ. The diagnosis of mild cognitive impairment due to AD: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for AD. *Alzheimer's & Dementia*. 2011; 7:270–9.
8. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC. The diagnosis of dementia due to AD: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for AD. *Alzheimer's & Dementia*. 2011; 7:263–9.
9. Hardy J, Selkoe DJ. The amyloid hypothesis of AD: progress and problems on the road to therapeutics. *Science*. 2002; 297:353–356. [PubMed: 12130773]
10. Knopman DS, Jack CR, Wiste HJ, Weigand SD, Vemuri P, Lowe VJ, Roberts RO. Brain injury biomarkers are not dependent on β -amyloid in normal elderly. *Annals of Neurology*. 2013; 73:472–480. (2013). [PubMed: 23424032]
11. Jack CR Jr. PART and SNAP. *Acta neuropathologica*. 2014; 128:773–6. [PubMed: 25380757]
12. Jack CR Jr, Knopman DS, Chételat G, Dickson D, Fagan AM, Frisoni GB, Jagust W, Mormino EC, Petersen RC, Sperling RA, Van Der Flier WM. Suspected non-Alzheimer disease pathophysiology – concept and controversy. *Nature Reviews Neurology*. 2016; 12:117–124. [PubMed: 26782335]
13. Jack CR, Therneau TM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, Senjem ML. Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. *The Lancet Neurology*. 2016; 15:56–64. [PubMed: 26597325]
14. Brookmeyer R, Abdalla N, Kawas CH, Corrada MM. Forecasting the prevalence of preclinical and clinical AD in the United States. *Alzheimer's & Dementia*. 2017 Dec 7.
15. Vos SJ, Verhey F, Frölich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rütther E, Nobili F, Morbelli S, Frisoni GB. Prevalence and prognosis of AD at the mild cognitive impairment stage. *Brain*. 2015; 138:1327–1338. [PubMed: 25693589]
16. Human Mortality Database. University of California; Berkeley (USA): Max Planck Institute for Demographic Research; Germany: Available at www.mortality.org (downloaded on 4/1/2016)
17. Vassilaki M, Cha RH, Aakre JA, Therneau TM, Geda YE, Mielke MM, Knopman DS, Petersen RC, Roberts RO. Mortality in mild cognitive impairment varies by subtype, sex, and lifestyle factors: the mayo clinic study of aging. *Journal of Alzheimer's Disease*. 2015; 45:1237–45.
18. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, Barnes LL, Fox JH, Bach J. Natural history of mild cognitive impairment in older persons. *Neurology*. 2002; 59:198–205. [PubMed: 12136057]
19. Wilson RS, Aggarwal NT, Barnes LL, Bienias JL, de Leon CF, Evans DA. Biracial population study of mortality in mild cognitive impairment and Alzheimer disease. *Archives of Neurology*. 2009; 66:767–72. [PubMed: 19506138]
20. Contador I, Bermejo-Pareja F, Mitchell AJ, Trincado R, Villarejo A, Sánchez-Ferro Á, Benito-León J. Cause of death in mild cognitive impairment: a prospective study (NEDICES). *European Journal of Neurology*. 2014; 21:253. [PubMed: 24128182]
21. Luck T, Riedel-Heller SG, Roehr S, Wiese B, Leeden C, Hessler K, Bickel H, Pentzek M, König HH, Werle J, Mamone S. Mortality in Incident Cognitive Impairment: Results of the Prospective

- AgeCoDe Study. *Journal of the American Geriatrics Society*. 2017; 65:738–46. [PubMed: 27991650]
22. Gail MH. Personalized estimates of breast cancer risk in clinical practice and public health. *Statistics in Medicine*. 2011; 30:1090–104. [PubMed: 21337591]
 23. Pfeiffer R, Gail MH. *Absolute Risk: Methods and Applications in Clinical Management and Public Health, Monographs on Statistics and Applied Probability* 154. CRC Press; Boca Raton FL: 2017.
 24. Ott A, Breteler MM, Harskamp FV, Stijnen T, Hofman A. Incidence and risk of dementia: the Rotterdam Study. *American Journal of Epidemiology*. 1998; 147:574–80. [PubMed: 9521184]
 25. Hofman A, Grobbee DE, De Jong PT, Van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. *European Journal of Epidemiology*. 1991; 7:403–22. [PubMed: 1833235]
 26. Fishman E. Risk of Developing Dementia at Older Ages in the United States. *Demography*. 2017; 54:1897–919. [PubMed: 28776169]
 27. Langa KM, Plassman BL, Wallace RB, Herzog AR, Heeringa SG, Ofstedal MB, Burke JR, Fisher GG, Fultz NH, Hurd MD, Potter GG. The Aging, Demographics, and Memory Study: study design and methods. *Neuroepidemiology*. 2005; 25:181–91. [PubMed: 16103729]
 28. Carone M, Asgharian M, Jewell NP. Estimating the lifetime risk of dementia in the Canadian elderly population using cross-sectional cohort survival data. *Journal of the American Statistical Association*. 2014; 109:24–35. [PubMed: 26139951]
 29. Canadian Study of Health and Aging Working Group. The incidence of dementia in Canada. *Neurology*. 2000; 55:66–72. [PubMed: 10891908]
 30. Weuve J, Hebert LE, Scherr PA, Evans DA. Deaths in the United States among persons with AD (2010–2050). *Alzheimer's & Dementia*. 2014; 10:e40–6.
 31. James BD, Leurgans SE, Hebert LE, Scherr PA, Yaffe K, Bennett DA. Contribution of Alzheimer disease to mortality in the United States. *Neurology*. 2014; 82:1045–50. [PubMed: 24598707]
 32. Murphy SL, Xu J, Kochanek KD. Deaths: Final data for 2010. *National Vital Statistics Reports*. 2013; 61(4)
 33. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of AD. *Alzheimer's & Dementia*. 2007; 3:186–91.
 34. Jack CR, Wiste HJ, Weigand SD, Knopman DS, Mielke MM, Vemuri P, Machulda MM. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. *Brain*. 2015; 138:3747–3759. [PubMed: 26428666]
 35. Langa KM, Larson EB, Crimmins EM, Faul JD, Levine DA, Kabeto MU, Weir DR. A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012. *JAMA Internal Medicine*. 2017; 77:51–8.
 36. Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. *New England Journal of Medicine*. 2016; 374:523–32. [PubMed: 26863354]
 37. Seshadri S, Wolf PA, Beiser A, Au R, McNulty K, White R, D'agostino RB. Lifetime risk of dementia and AD The impact of mortality on risk estimates in the Framingham Study. *Neurology*. 1997; 49:1498–504. [PubMed: 9409336]
 38. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. *Annals of Neurology*. 2010; 67:122–31. [PubMed: 20186853]
 39. Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szeke C, Salvado O, Martins R. Longitudinal assessment of A β and cognition in aging and Alzheimer disease. *Annals of Neurology*. 2011; 69:181–92. [PubMed: 21280088]
 40. Jack CR, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, Lowe VJ, Senjem ML, Gunter JL, Preboske GM, Pankratz VS. Age-specific population frequencies of cerebral β -amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study. *The Lancet Neurology*. 2014; 13:997–1005. [PubMed: 25201514]
 41. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ, Aalten P, Aarsland D, Alcolea D, Alexander M. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *JAMA*. 2015; 313:1924–38. [PubMed: 25988462]

42. Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, Petersen RC. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. *Neurology*. 2016; 87(5):539–47. [PubMed: 27371494]
43. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. *Journal of Nuclear Medicine*. 2013; 54:476–90. [PubMed: 23359661]
44. Moyer VA. Screening for Cognitive Impairment in Older Adults: US Preventive Services Task Force Recommendation Statement. *Annals of Internal Medicine*. 2014; 160:791–7. [PubMed: 24663815]
45. Roberts JS, Dunn LB, Rabinovici GD. Amyloid imaging, risk disclosure and AD: ethical and practical issues. *Neurodegenerative Disease Management*. 2013; 3:219–29. [PubMed: 26167204]
46. Porteri C, Albanese E, Scerri C, Carrillo MC, Snyder HM, Martensson B, Baker M, Giacobini E, Boccardi M, Winblad B, Frisoni GB. The biomarker-based diagnosis of AD. 1—ethical and societal issues. *Neurobiology of Aging*. 2017; 52:132–40. [PubMed: 28317644]

HIGHLIGHTS

- Estimated lifetime risks of AD dementia accounting for preclinical disease state
- Most persons with preclinical AD will not develop AD dementia during their lifetimes
- Lifetime risks vary considerably by age, gender and preclinical or clinical disease state
- Lifetime risks assist in the interpretation of the clinical significance of biomarker screening tests for preclinical AD

RESEARCH IN CONTEXT

Systematic Review

The authors searched PubMed for articles on lifetime risks of AD dementia. Lifetime risks are the probabilities that individuals progress to AD dementia during their natural lifespans. Here we report the first estimates of lifetime and ten-year risks of AD dementia that account for age, gender, biomarker screening tests for preclinical disease including amyloidosis or neurodegeneration, and presence or absence of mild cognitive impairment.

Interpretation

We find that lifetime risks for AD dementia vary considerably by age, gender and pre-clinical disease state. Most persons with preclinical AD will not develop AD dementia during their lifetimes.

Future Directions

Persons with preclinical AD may never experience any clinical symptoms during their lifetimes because of its long and variable preclinical period and the high mortality rates in elderly populations. Lifetime risks assist in the interpretation of the clinical significance of biomarker screening tests for preclinical AD.

Figure 1.
Multistate Model used to estimate lifetime risks of AD dementia

Table 1

Lifetime risks (%) of AD dementia for females based on screening for Amyloidosis (A), Neurodegeneration (N) and mild cognitive impairment (MCI) by age; lower and upper bounds in brackets.

Age	Normal State 1	A State 2	N State 3	A&N State 4	MCI&A&N State 5	MCI&N State 6
60	20.1 [10.6-34.0]	31.0 [20.7-42.4]	30.3 [15.9-53.2]	41.9 [31.2-52.7]	95.6 [94.8-96.3]	78.1 [70.9-84.9]
65	18.7 [9.7-32.0]	29.3 [19.4-40.5]	27.6 [14.5-48.0]	40.8 [30.3-51.4]	93.6 [92.3-94.5]	71.4 [63.7-79.2]
70	16.6 [8.4-29.0]	26.9 [17.6-37.6]	24.5 [12.9-42.3]	38.9 [28.7-49.3]	90.1 [88.2-91.4]	63.0 [55.1-71.6]
75	13.8 [6.8-24.9]	23.5 [15.1-33.4]	20.8 [10.8-36.0]	35.9 [26.2-45.8]	84.7 [82.1-86.7]	53.2 [45.5-62.1]
80	10.4 [4.9-19.5]	19.1 [12.0-27.8]	16.5 [8.5-29.0]	31.2 [22.4-40.3]	76.2 [72.8-78.9]	42.0 [35.1-50.5]
85	7.1 [3.2-13.7]	13.8 [8.4-20.6]	11.9 [6.0-21.2]	24.7 [17.4-32.5]	63.8 [59.7-67.2]	30.3 [24.8-37.5]
90	4.1 [1.8-8.4]	8.4 [4.9-13.0]	7.3 [3.6-13.4]	16.9 [11.6-22.6]	46.7 [42.7-50.2]	19.1 [15.4-24.3]

10-year risks (%) of AD dementia for females based on screening for Amyloidosis (A), Neurodegeneration (N) and mild cognitive impairment (MCI) by age; lower and upper bounds in brackets

Table 2

Age	Normal State 1	A State 2	N State 3	A&N State 4	MCI&A&N State 5	MCI&N State 6
60	0.2 [.06-.8]	1.3 [.6-2.5]	3.6 [1.1-14.2]	7.1 [4.5-10.9]	93.5 [91.1-95.0]	57.2 [48.2-67.9]
65	0.5 [.14-1.8]	2.5 [1.2-4.9]	4.3 [1.4-15.0]	10.7 [6.8-16.2]	91.7 [89.2-93.5]	55.4 [46.6-65.8]
70	1.1 [.34-3.5]	4.7 [2.4-8.7]	5.5 [2.0-16.6]	15.5 [10.0-22.8]	88.6 [85.8-90.6]	52.2 [43.8-62.4]
75	2.2 [.74-6.5]	7.8 [4.1-14.0]	7.3 [2.9-19.0]	20.8 [13.7-29.7]	83.8 [80.7-86.2]	47.4 [39.6-57.0]
80	3.7 [1.3-9.8]	11.1 [6.0-18.7]	9.3 [3.9-20.9]	24.4 [16.4-33.8]	75.8 [72.2-78.7]	40.0 [33.1-48.6]
85	4.7 [1.8-11.0]	11.5 [6.5-18.5]	9.7 [4.3-19.3]	23.1 [15.8-31.2]	63.7 [59.6-67.2]	30.0 [24.5-37.2]
90	3.8 [1.5-8.2]	8.2 [4.7-12.9]	7.1 [3.3-13.3]	16.8 [11.5-22.6]	46.7 [42.7-50.2]	19.1 [15.3-24.3]

Table 3

Lifetime risks (%) of AD dementia for males based on screening for Amyloidosis (A), Neurodegeneration (N) and mild cognitive impairment (MCI) by age; lower and upper bounds in brackets.

Age	Normal State 1	A State 2	N State 3	A&N State 4	MCI&A&N State 5	MCI&N State 6
60	13.9 [6.9-25.1]	23.1 [14.9-33.0]	23.1 [11.4-44.3]	33.6 [24.4-43.5]	92.9 [91.7-93.9]	71.7 [64.3-79.2]
65	12.9 [6.3-23.6]	21.9 [13.9-31.4]	20.8 [10.3-39.4]	32.9 [23.8-42.7]	90.4 [88.6-91.7]	64.9 [57.1-73.2]
70	11.3 [5.4-21.2]	19.9 [12.5-29.0]	18.2 [9.0-34.0]	31.3 [22.5-40.7]	86.0 [83.6-87.8]	56.3 [48.6-65.0]
75	9.3 [4.3-17.8]	17.2 [10.6-25.4]	15.2 [7.5-28.2]	28.6 [20.3-37.5]	79.5 [76.5-82.0]	46.6 [39.4-55.2]
80	6.8 [3.0-13.5]	13.6 [8.2-20.6]	11.7 [5.7-21.9]	24.5 [17.1-32.5]	69.9 [66.1-73.0]	36.0 [29.8-43.8]
85	4.4 [1.9-9.2]	9.5 [5.6-14.8]	8.1 [3.9-15.5]	18.9 [13.0-25.5]	56.7 [52.6-60.2]	25.3 [20.6-31.7]
90	2.4 [1.0-5.2]	5.4 [3.1-8.8]	4.7 [2.2-9.2]	12.4 [8.3-17.0]	40.2 [36.4-43.5]	15.6 [12.5-20.0]

10-year risks (%) of AD dementia for males based on screening for Amyloidosis (A), Neurodegeneration (N) and mild cognitive impairment (MCI) by age; lower and upper bounds in brackets.

Table 4

Age	Normal State 1	A State 2	N State 3	A&N State 4	MCI&A&N State 5	MCI&N State 6
60	0.2 [.05-0.8]	1.2 [.6-2.4]	3.4 [1.0-13.5]	6.7 [4.3-10.4]	91.1 [88.5-92.8]	54.9 [46.2-65.3]
65	0.4 [.13-1.6]	2.3 [1.2-4.5]	4.0 [1.3-14.1]	10.1 [6.4-15.2]	88.8 [86.1-90.8]	52.6 [44.1-62.7]
70	1.0 [.3-3.2]	4.2 [2.1-7.9]	5.0 [1.8-15.1]	14.2 [9.2-21.0]	84.9 [81.9-87.2]	48.7 [40.7-58.4]
75	1.9 [.6-5.5]	6.8 [3.5-12.1]	6.4 [2.5-16.6]	18.4 [12.0-26.4]	79.0 [75.5-81.6]	43.0 [35.8-52.0]
80	2.9 [1.0-7.7]	8.9 [4.8-15.1]	7.5 [3.1-17.1]	20.4 [13.6-28.5]	69.7 [65.8-72.9]	34.9 [28.8-42.8]
85	3.3 [1.2-7.8]	8.4 [4.7-13.8]	7.1 [3.1-14.6]	18.1 [12.2-24.9]	56.6 [52.5-60.2]	25.2 [20.5-31.6]
90	2.3 [.9-5.1]	5.4 [3.0-8.7]	4.6 [2.1-9.2]	12.4 [8.3-17.0]	40.2 [36.4-43.5]	15.6 [12.5-20.0]

Table 5

Comparison of lifetime risks of AD dementia (%) by age and gender based on the multistate model (ranges) and the Framingham Study (95% CIs) [5]. Also shown are lifetime risks for all-cause dementia based on the Rotterdam Study [24] and the ADAMS Study [26]. N.R. indicates not reported.

Age	Multistate (AD)	Framingham (AD)	Rotterdam (all dementia)	ADAMS (all dementia)
<u>FEMALE</u>				
60	24.4 [13.1-39.8]	N.R.	N.R.	N.R.
65	25.2 [13.7-40.9]	17.2 [15.0-19.4]	34.5	N.R.
70	26.2 [14.3-41.9]	N.R.	N.R.	34.7
75	27.3 [15.1-42.6]	18.5 [16.2-20.9]	35.4	34.1
80	27.7 [15.7-42.1]	N.R.	N.R.	32.9
85	26.8 [15.7-39.5]	20.3 [17.0-23.6]	32.7	31.2
90	23.2 [14.0-33.2]	N.R.	N.R.	29.3
<u>MALE</u>				
60	17.6 [9.0-30.8]	N.R.	N.R.	N.R.
65	18.7 [9.6-32.3]	9.1 [7.2-11.1]	16.0	N.R.
70	19.9 [10.3-33.7]	N.R.	N.R.	26.9
75	21.1 [11.2-34.8]	10.2 [7.9-12.5]	18.0	27.1
80	21.8 [11.9-34.7]	N.R.	N.R.	26.7
85	21.2 [12.0-32.5]	12.1 [8.2-15.9]	12.3	25.7
90	18.2 [10.6-27.0]	N.R.	N.R.	24.7